BeOne Medicines Ltd. (BEIGF) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-06

Key Insights

BeOne Medicines announced Q1 2026 financial results on May 6, 2026, indicating the company is actively reporting operational performance to shareholders and maintaining SEC compliance.
The company is incorporated in Switzerland with dual listings on Nasdaq (ticker ONC as ADSs) and Hong Kong Stock Exchange (06160), indicating a significant international presence and investor base across multiple markets.
The 8-K filing is limited to earnings announcement with no disclosure of material agreements, leadership changes, or significant business developments, suggesting this is a routine quarterly earnings report rather than a transformational event.

Want the newest filings?

This analysis covers the filing from 2026-05-06. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-14

BeOne Medicines Ltd. filed its 2025 Annual Report with the STAR Market in China, which contains additional financial information prepared under PRC GAAP that differs from U.S. GAAP.
The company provided a summary of the material differences between PRC GAAP and U.S. GAAP financial metrics, including gross profit margin, R&D expenses, and production/sales/inventory data.
As a dual-listed company, the filing of the STAR Annual Report provides transparency into the company's financial performance and accounting practices in China, which may be of interest to investors.

Filed: 2026-02-26

BeOne Medicines reported strong financial results for Q4 and full year 2025, highlighting the global success of its flagship cancer drug BRUKINSA and its leadership in the oncology space.
The company's American Depositary Shares (ADSs) are traded on the Nasdaq Global Select Market, while its ordinary shares are listed on The Stock Exchange of Hong Kong Limited, indicating a diversified global presence.
The filing does not mention any material agreements, leadership changes, or earnings surprises, suggesting a relatively routine quarterly update.

Other reports for BeOne Medicines Ltd.

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.